Skip to main content
Contact Us
Subscribe
E-Edition
44°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Affimed Ord Shs
(NQ:
AFMD
)
2.150
-0.030 (-1.38%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Affimed Ord Shs
< Previous
1
2
3
4
5
6
7
Next >
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
December 09, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
December 09, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024
From
Affimed N.V.
Via
GlobeNewswire
A Look Ahead: Affimed's Earnings Forecast
November 13, 2024
Via
Benzinga
Why Affimed Shares Are Soaring
June 03, 2024
Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).
Via
Benzinga
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
December 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports Third Quarter 2024 Financial Results & Business Update
November 14, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
November 06, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
November 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
Affimed to Present at the Cantor Global Healthcare Conference 2024
September 10, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Reports Second Quarter 2024 Financial Results & Business Update
September 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Appoints Shawn M. Leland as Chief Executive Officer
September 03, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
August 29, 2024
From
Affimed N.V.
Via
GlobeNewswire
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
June 12, 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Affimed Reports First Quarter 2024 Financial Results & Business Update
June 12, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
June 05, 2024
From
Affimed N.V.
Via
GlobeNewswire
Why Is German Biotech Affimed Stock Soaring On Monday?
June 03, 2024
Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24...
Via
Benzinga
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
June 01, 2024
From
Affimed N.V.
Via
GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
May 29, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
May 28, 2024
From
Affimed N.V.
Via
GlobeNewswire
7 Penny Biotech Stocks to Triple Your Investment
May 28, 2024
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
Via
InvestorPlace
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
May 23, 2024
From
Affimed N.V.
Via
GlobeNewswire
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
May 17, 2024
Lower interest rates will bring speculators back into small-cap stocks; with that in mind here are three small-cap stocks to buy now.
Via
InvestorPlace
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14, 2024
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
April 24, 2024
From
Affimed N.V.
Via
GlobeNewswire
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
March 28, 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Affimed Reports 2023 Financial Results and Operational Progress
March 28, 2024
From
Affimed N.V.
Via
GlobeNewswire
Earnings Scheduled For March 28, 2024
March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.